The Centre for Process Innovation (CPI) is part of a UK based consortium developing technologies that will spearhead the commercialisation of intelligent pharmaceutical packaging.
The project titled ‘REMEDIES’, launched in 2014 and due for completion March 2018, is headed by GlaxoSmithKline with research led by the University of Cambridge’s Institute for Manufacturing. It brings together key players in the pharmaceutical supply chain to bring new emerging technologies to market which have the potential to improve medicine manufacturing and supply and offer more personalised, faster and cheaper drug delivery.
The UK’s pharmaceutical sector makes a major contribution to the UK economy but there remain significant market challenges to address current supply chain inefficiencies which add costs and reduce productivity. The REMEDIES project seeks to redefine the supply chain of the future, provide innovative ways to tackle inefficiencies and capitalise on new opportunities to position the UK as a gloabl leader in pharmaceutical manufacturing .
The project focuses on five technology based application themes spanning both ends of clinical and commercial supply chains. These themes address; active pharmaceutical ingredient manufacturing, primary to secondary manufacturing, super-critical fluid technology, agile packaging and printed electronics. CPI’s role is to collaborate with the project partners who include GlaxoSmithKline and AstraZeneca to develop and scale up ‘smart packaging’ concepts incorporating printed electronics. The partners will work together to commercialise product prototypes and create a market ready supply chain that facilitates mass market adoption within the UK.